Form 4: Akari Therapeutics Director Increases Stake with Share Purchases

Director Samir Rashmikant Patel acquired 3.6 million ordinary shares of Akari Therapeutics at $0.0005 per share through PranaBio Investments LLC.

Summary

• Samir Rashmikant Patel, a director of Akari Therapeutics, acquired 3,200,000 ordinary shares on December 26, 2024, at a price of $0.0005 per share.
• He further acquired 400,000 ordinary shares on December 27, 2024, also at $0.0005 per share.
• These transactions were made through PranaBio Investments LLC, indicating indirect ownership.
• Following these purchases, Mr. Patel's indirect holdings through PranaBio Investments LLC increased to 5,249,303,500 ordinary shares.
• Mr. Patel also directly owns 91,396,000 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by a company director. While the purchase is a positive sign, it's not a major event that would significantly alter the company's outlook.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The increased stake by a director can be seen as a positive signal to the market.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
• The transactions are relatively small in terms of total value, but the increase in shareholding by a director is a notable event.
• Similar filings are made by directors and officers of all publicly traded companies, such as those in the biotechnology sector like Amgen or Regeneron.

Stakeholder Impact

• The increased shareholding by a director may positively influence investor confidence.
• The transaction has no direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Akari Therapeutics, Share Acquisition, Director, Insider Trading, Ordinary Shares, PranaBio Investments LLC, SEC Form 4